Trial Condition(s):

Deep vein thrombosis (DVT), pulmonary embolism (PE)

The EINSTEIN DVT study

Bayer Identifier:

11702

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2006-004495-13

EU CT Number:

Not Available

Study Completed

Trial Purpose

Primary Objective:
To evaluate whether rivaroxaban is at least as effective as enoxaparin/VKA (VKA: either warfarin or acenocoumarol) in the treatment of subjects with acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism for the prevention of recurrent venous thromboembolic events.

Secondary Objective:
The principal safety objective was the evaluation of major and clinically relevant non-major bleeding events.

Inclusion Criteria

-  Confirmed acute symptomatic proximal DVT without symptomatic PE

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

3449

Trial Dates

March2007

April2010

Phase

Could I receive a placebo?

Products

Xarelto (Rivaroxaban, BAY59-7939)

Accepts Healthy Volunteers

Where to Participate

Locations

Status

Locations	Status

Deep vein thrombosis (DVT), pulmonary embolism (PE)

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

18 Years

95 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information